Showing 3241-3250 of 7750 results for "".
- Rare Skin Disease Update: Abeona's EB-101 Performs Well in a Phase 3 study of RDEBhttps://practicaldermatology.com/news/rare-skin-disease-update-abeonas-eb-101-performs-well-in-a-phase-3-study-of-rdeb/2461715/Abeona Therapeutics Inc.’s investigational EB-101 performed well in a Phase 3 study of recessive dystrophic epidermolysis bullosa (RDEB). Both co-primary endpoints were met, with the majority (81.4%) of randomized EB-101–treated wounds demonstrating ≥50% healing compared
- Participating in an AD Trial: Weighing What Matters Most to Patients and Parentshttps://practicaldermatology.com/news/participating-in-an-ad-trial-weighing-what-matters-most-to-patients-and-parents/2461714/Key differences exist between what adults with eczema value for themselves in clinical trial participation versus what parents find important for their kids with this chronic skin disease, according to new research from the
- Mindfulness and Self-compassion Training Improve QOL for AD Patientshttps://practicaldermatology.com/news/mindfulness-and-self-compassion-training-improve-qol-for-ad-patients/2461713/Online group mindfulness and self-compassion training improves quality of life in adults with atopic dermatitis (AD). In this randomized clinical trial of 107 adults with AD, mindfulness and self-compassion training in addition to usual care showed significantly greater improvement
- Cutera Update: Agreements Made With Pura Vida and RTW; New Board Members Appointedhttps://practicaldermatology.com/news/cutera-update-agreements-made-with-pura-vida-and-rtw-new-board-members-appointed/2461712/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an
- Evolus Acquires Exclusive US Distributor Rights to Evolysse Line of Dermal Fillershttps://practicaldermatology.com/news/evolus-acquires-exclusive-us-distributor-rights-to-evolysse-line-of-dermal-fillers/2461710/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- American Academy of Dermatology Survey Shows Generation Z Adults are Unfamiliar with Sunburn and Tanning Riskshttps://practicaldermatology.com/news/american-academy-of-dermatology-survey-shows-generation-z-adults-are-unfamiliar-with-sunburn-and-tanning-risks/2461708/A recent American Academy of Dermatology survey of more than 1,000 US adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths, according to an AAD news release. According to the surv
- DermTech Appoints Bret Christensen as New President and CEOhttps://practicaldermatology.com/news/dermtech-appoints-bret-christensen-as-new-president-and-ceo/2461707/DermTech announced the appointment of Bret Christensen as president, chief executive officer, and a member of the board of directors. Mr. Christensen, who was previously chief commercial officer of Insulet, succeeds Dr. John Dobak, who stepped down as president, CEO and a dir
- Lycored: Study Shows Preventive Effects and Protective Potential of Astaxanthin on Collagen Damagehttps://practicaldermatology.com/news/lycored-study-shows-preventive-effects-and-protective-potential-of-astaxanthin-on-collagen-damage/2461706/A study recently found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health. The study,
- FDA Set to Review Ortho Derm's Triple Combo Acne Gelhttps://practicaldermatology.com/news/fda-set-to-review-ortho-derms-triple-combo-acne-gel/2461705/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Ortho Dermatologics’ investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel. The Prescription Drug User Fee Act (PDUFA) action date is set for October 20, 2023, accordin